Background: Cases of psoriasis associated with Tocilizumab (TCZ) are scarce.
Objective: To describe a new case of TCZ-associated psoriasis and to perform a case-based review of similar cases.
Methods: We searched Medline/Pubmed, Embase, Scopus, Web of Science, and Directory of Open Access Journals databases using the terms « Tocilizumab » and « Psoriasis » in the French and English literature.
Results: We report a 70-year-old woman with a history of Rheumatoid Arthritis who developed Infliximab-induced plaque psoriatic eruption of the soles and palms, that resolved after Infliximab interruption, then relapsed after TCZ relay, and eventually resolved after TCZ interruption. Including our case, we identified 16 cases of TCZ-induced psoriatic eruption. Three (21%) out of 14 patients had a history of cutaneous psoriasis - data were not available for 2 patients. Eight (50%) patients had previously received TNFα antagonists. TCZ was stopped for 10 patients and continued for 4 patients. For the 2 remaining patients, the interval between two injections of TCZ was shortened. All the patients with available follow-up data had an improvement of the eruption within 4 weeks.
Conclusion: To conclude, in case of TCZ-induced psoriatic eruption and in light of the published cases, we suggest using topical steroids and reassessing the patient 4 weeks later. If no healing is obtained, we suggest stopping TCZ, and treating the underlying disease with another drug. When no other drug is available, while waiting for more data regarding the value of IL-6 levels, it can be discussed to increase TCZ regimen, as it has been successful for 2 authors. Efficacy assessment of the chosen attitude should not take place before 4 weeks.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00296-024-05663-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Two rashes, one patient: Enfortumab vedotin-induced interface dermatitis and pembrolizumab-induced psoriatic disease treated with ixekizumab.
JAAD Case Rep
November 2024
Department of Dermatology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
First reported case of thymoma-associated multiorgan autoimmunity induced by COVID-19.
J Dermatol
December 2024
Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
Article Synopsis
- - Thymoma-associated multiorgan autoimmunity (TAMA) involves symptoms like skin issues, liver dysfunction, and enteritis, similar to graft-versus-host disease (GVHD), but occurs without prior stem cell or bone marrow transplants and is linked to thymoma.
- - A 64-year-old woman with myasthenia gravis and thymoma developed skin rashes after a COVID-19 infection, initially suspected to be a drug reaction, but despite treatment adjustments, her condition worsened and led to severe gastrointestinal symptoms.
- - The patient's diagnosis of TAMA was confirmed through skin biopsy showing GVHD-like changes, and her decline included complications from infections, ultimately resulting in her death, with COVID-
Leflunomide induced fatal dress syndrome need liver transplantation.
Hepatol Forum
September 2024
Department of Gastroenterology, Inonu University School of Medicine, Malatya, Turkiye.
Article Synopsis
- DRESS syndrome is a serious allergic reaction to drugs leading to severe blood and organ issues, which may include symptoms like skin rashes and organ failure.* -
- A 36-year-old woman developed DRESS syndrome after starting Leflunomide for psoriatic arthritis, resulting in bloody diarrhea, skin rashes, and severe liver failure.* -
- Despite undergoing a liver transplant from her son, the patient unfortunately passed away two days later due to multiple organ failures, highlighting the high mortality rate associated with DRESS syndrome.*
Eczematous eruption during bimekizumab treatment in a psoriatic patient previously treated with secukinumab.
Skin Health Dis
October 2024
Article Synopsis
- The text discusses cases of skin rashes, specifically eczema, linked to treatments with anti-IL17A and anti-IL17 receptor medications.
- The patient in the case had previously been on an IL-17A inhibitor for two years without experiencing any eczematous reactions.
- However, after starting treatment with bimekizumab, which targets both IL-17A and IL-17F, the patient developed skin eruptions.
Bimekizumab-induced acral pustulovesicular eruption in a patient with psoriatic arthritis.
J Dermatol
September 2024
Department of Dermatology, Fukushima Medical University, Fukushima, Japan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!